| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Proto-Oncogene Proteins c-akt | 17 | 2024 | 493 | 2.700 |
Why?
|
| Exotropia | 4 | 2023 | 14 | 1.900 |
Why?
|
| MicroRNAs | 10 | 2024 | 838 | 1.780 |
Why?
|
| Hepatitis B virus | 3 | 2024 | 142 | 1.770 |
Why?
|
| Phosphatidylinositol 3-Kinases | 8 | 2024 | 343 | 1.770 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 3 | 2023 | 85 | 1.650 |
Why?
|
| Signal Transduction | 31 | 2024 | 4511 | 1.610 |
Why?
|
| Strabismus | 2 | 2023 | 47 | 1.560 |
Why?
|
| Phosphoprotein Phosphatases | 10 | 2021 | 114 | 1.540 |
Why?
|
| Prostatic Neoplasms | 6 | 2023 | 1516 | 1.300 |
Why?
|
| Cell Line, Tumor | 28 | 2024 | 3290 | 1.230 |
Why?
|
| Cell Movement | 8 | 2024 | 838 | 1.220 |
Why?
|
| Hepatitis B | 4 | 2024 | 162 | 1.190 |
Why?
|
| Receptors, Androgen | 5 | 2023 | 408 | 1.100 |
Why?
|
| RNA Helicases | 3 | 2022 | 61 | 1.060 |
Why?
|
| Macrophages | 4 | 2024 | 611 | 1.060 |
Why?
|
| MAP Kinase Signaling System | 4 | 2021 | 320 | 1.020 |
Why?
|
| Apoptosis | 14 | 2024 | 1790 | 0.990 |
Why?
|
| Cell Proliferation | 13 | 2024 | 2311 | 0.950 |
Why?
|
| Exosomes | 1 | 2024 | 41 | 0.930 |
Why?
|
| Gene Expression Regulation, Neoplastic | 12 | 2024 | 1889 | 0.840 |
Why?
|
| Viral Proteins | 2 | 2015 | 348 | 0.830 |
Why?
|
| Interleukin-8 | 4 | 2020 | 209 | 0.830 |
Why?
|
| GATA2 Transcription Factor | 1 | 2022 | 45 | 0.820 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2024 | 119 | 0.810 |
Why?
|
| Esotropia | 1 | 2022 | 11 | 0.800 |
Why?
|
| PAX6 Transcription Factor | 1 | 2021 | 37 | 0.770 |
Why?
|
| Aniridia | 1 | 2021 | 12 | 0.770 |
Why?
|
| NF-kappa B | 3 | 2024 | 461 | 0.730 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2022 | 346 | 0.690 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 2019 | 12 | 0.690 |
Why?
|
| Diterpenes | 1 | 2019 | 28 | 0.680 |
Why?
|
| Colorectal Neoplasms | 3 | 2022 | 559 | 0.660 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2019 | 105 | 0.630 |
Why?
|
| TOR Serine-Threonine Kinases | 11 | 2022 | 428 | 0.630 |
Why?
|
| Colonic Neoplasms | 3 | 2024 | 247 | 0.620 |
Why?
|
| Atherosclerosis | 2 | 2024 | 828 | 0.600 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2024 | 957 | 0.580 |
Why?
|
| Liver Neoplasms | 3 | 2024 | 1386 | 0.580 |
Why?
|
| Hepatocytes | 6 | 2021 | 250 | 0.570 |
Why?
|
| Retinitis Pigmentosa | 2 | 2014 | 83 | 0.560 |
Why?
|
| Gene Expression Regulation | 7 | 2017 | 2534 | 0.550 |
Why?
|
| Commiphora | 2 | 2013 | 2 | 0.550 |
Why?
|
| Bone Morphogenetic Proteins | 2 | 2014 | 123 | 0.550 |
Why?
|
| Phosphorylation | 16 | 2016 | 1613 | 0.520 |
Why?
|
| Smad Proteins | 1 | 2016 | 43 | 0.510 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2016 | 101 | 0.500 |
Why?
|
| Abnormalities, Multiple | 1 | 2021 | 962 | 0.500 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2024 | 671 | 0.490 |
Why?
|
| Epithelial Cells | 1 | 2019 | 907 | 0.490 |
Why?
|
| Mice | 26 | 2024 | 17546 | 0.480 |
Why?
|
| Humans | 62 | 2024 | 122296 | 0.470 |
Why?
|
| Androgen Antagonists | 4 | 2023 | 114 | 0.470 |
Why?
|
| Oxidative Stress | 1 | 2019 | 798 | 0.470 |
Why?
|
| Mutation | 4 | 2015 | 5734 | 0.450 |
Why?
|
| Triterpenes | 1 | 2013 | 21 | 0.450 |
Why?
|
| DNA, Viral | 1 | 2015 | 492 | 0.450 |
Why?
|
| Animals | 33 | 2024 | 33721 | 0.440 |
Why?
|
| Bardet-Biedl Syndrome | 1 | 2013 | 38 | 0.440 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2013 | 102 | 0.420 |
Why?
|
| cdc25 Phosphatases | 1 | 2012 | 22 | 0.410 |
Why?
|
| HEK293 Cells | 5 | 2021 | 741 | 0.410 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2012 | 90 | 0.400 |
Why?
|
| Interleukin-6 | 6 | 2024 | 394 | 0.400 |
Why?
|
| RNA Interference | 7 | 2020 | 496 | 0.390 |
Why?
|
| Lung | 1 | 2019 | 1476 | 0.390 |
Why?
|
| Epithelial-Mesenchymal Transition | 5 | 2022 | 217 | 0.390 |
Why?
|
| T-Box Domain Proteins | 2 | 2015 | 117 | 0.390 |
Why?
|
| PTEN Phosphohydrolase | 4 | 2022 | 262 | 0.390 |
Why?
|
| China | 4 | 2023 | 224 | 0.390 |
Why?
|
| Genetic Association Studies | 1 | 2014 | 738 | 0.370 |
Why?
|
| Myocytes, Cardiac | 2 | 2017 | 618 | 0.370 |
Why?
|
| Xenograft Model Antitumor Assays | 8 | 2024 | 874 | 0.360 |
Why?
|
| Phenotype | 5 | 2024 | 4151 | 0.350 |
Why?
|
| Mice, Nude | 5 | 2024 | 697 | 0.340 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 2023 | 207 | 0.340 |
Why?
|
| Pyridones | 3 | 2016 | 111 | 0.320 |
Why?
|
| Reactive Oxygen Species | 6 | 2020 | 479 | 0.320 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 630 | 0.320 |
Why?
|
| Blotting, Western | 10 | 2015 | 1104 | 0.310 |
Why?
|
| DNA Mutational Analysis | 3 | 2015 | 792 | 0.310 |
Why?
|
| Mice, Inbred C57BL | 11 | 2024 | 4366 | 0.300 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2011 | 457 | 0.300 |
Why?
|
| Cell Line | 11 | 2017 | 2782 | 0.280 |
Why?
|
| Cardiomyopathies | 1 | 2011 | 475 | 0.280 |
Why?
|
| Male | 24 | 2024 | 59522 | 0.270 |
Why?
|
| Cardiotoxicity | 2 | 2017 | 26 | 0.260 |
Why?
|
| Cell Differentiation | 5 | 2023 | 1935 | 0.260 |
Why?
|
| Androgens | 3 | 2023 | 257 | 0.250 |
Why?
|
| Mice, SCID | 3 | 2022 | 570 | 0.250 |
Why?
|
| Sirolimus | 3 | 2012 | 220 | 0.250 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2024 | 29 | 0.240 |
Why?
|
| Nuclear Proteins | 3 | 2018 | 1277 | 0.240 |
Why?
|
| THP-1 Cells | 1 | 2024 | 22 | 0.240 |
Why?
|
| Polysaccharides | 2 | 2017 | 142 | 0.240 |
Why?
|
| Gene Frequency | 3 | 2015 | 703 | 0.240 |
Why?
|
| Gene Expression | 4 | 2019 | 1579 | 0.240 |
Why?
|
| Neoplasms | 3 | 2023 | 2753 | 0.240 |
Why?
|
| Smad1 Protein | 2 | 2014 | 22 | 0.230 |
Why?
|
| Thioctic Acid | 1 | 2024 | 8 | 0.230 |
Why?
|
| Rhabdomyosarcoma | 3 | 2016 | 194 | 0.230 |
Why?
|
| Doxorubicin | 2 | 2017 | 307 | 0.230 |
Why?
|
| Open Reading Frames | 2 | 2015 | 211 | 0.230 |
Why?
|
| Butyric Acid | 1 | 2024 | 7 | 0.230 |
Why?
|
| rac1 GTP-Binding Protein | 3 | 2021 | 63 | 0.230 |
Why?
|
| Vision, Binocular | 2 | 2022 | 44 | 0.230 |
Why?
|
| G-Protein-Coupled Receptor Kinase 3 | 1 | 2023 | 11 | 0.220 |
Why?
|
| Enzyme Activation | 5 | 2019 | 621 | 0.220 |
Why?
|
| Oculomotor Muscles | 2 | 2022 | 63 | 0.220 |
Why?
|
| Histone Deacetylase 2 | 1 | 2023 | 16 | 0.220 |
Why?
|
| Antineoplastic Agents | 5 | 2024 | 1677 | 0.220 |
Why?
|
| Interleukin-4 | 1 | 2024 | 139 | 0.220 |
Why?
|
| 3-Phosphoinositide-Dependent Protein Kinases | 1 | 2023 | 18 | 0.220 |
Why?
|
| Kallikreins | 2 | 2021 | 26 | 0.220 |
Why?
|
| Interleukin-13 | 1 | 2024 | 95 | 0.220 |
Why?
|
| PPAR gamma | 1 | 2024 | 92 | 0.220 |
Why?
|
| Neoplasm Invasiveness | 4 | 2020 | 609 | 0.210 |
Why?
|
| Transforming Growth Factor beta | 3 | 2014 | 458 | 0.210 |
Why?
|
| Heart Failure | 2 | 2017 | 2125 | 0.210 |
Why?
|
| Water | 1 | 2024 | 181 | 0.210 |
Why?
|
| Interferon-alpha | 1 | 2024 | 221 | 0.210 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 3 | 2021 | 93 | 0.210 |
Why?
|
| Smad3 Protein | 2 | 2013 | 55 | 0.210 |
Why?
|
| Prostate-Specific Antigen | 2 | 2021 | 247 | 0.200 |
Why?
|
| Wearable Electronic Devices | 1 | 2024 | 101 | 0.200 |
Why?
|
| Liver | 4 | 2017 | 1851 | 0.200 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2024 | 525 | 0.200 |
Why?
|
| AMP-Activated Protein Kinases | 2 | 2016 | 165 | 0.200 |
Why?
|
| Flavonoids | 2 | 2020 | 78 | 0.190 |
Why?
|
| Cell Cycle | 3 | 2013 | 618 | 0.190 |
Why?
|
| Autophagy | 3 | 2020 | 390 | 0.190 |
Why?
|
| Eye | 1 | 2023 | 227 | 0.190 |
Why?
|
| Insulin Resistance | 2 | 2017 | 631 | 0.190 |
Why?
|
| Nitrogen | 2 | 2014 | 134 | 0.190 |
Why?
|
| Ophthalmologic Surgical Procedures | 1 | 2022 | 88 | 0.190 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2021 | 48 | 0.190 |
Why?
|
| Cadmium | 2 | 2011 | 29 | 0.190 |
Why?
|
| 3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 1 | 2020 | 3 | 0.180 |
Why?
|
| Finasteride | 1 | 2020 | 16 | 0.180 |
Why?
|
| Neuropeptides | 1 | 2021 | 112 | 0.180 |
Why?
|
| RNA, Messenger | 3 | 2024 | 2826 | 0.180 |
Why?
|
| RNA, Small Interfering | 4 | 2016 | 663 | 0.180 |
Why?
|
| Anoikis | 2 | 2022 | 6 | 0.180 |
Why?
|
| Cyclin B1 | 1 | 2020 | 9 | 0.180 |
Why?
|
| Caspase 3 | 3 | 2020 | 130 | 0.180 |
Why?
|
| Breast Neoplasms | 4 | 2022 | 2480 | 0.180 |
Why?
|
| Protein Phosphatase 2C | 3 | 2016 | 55 | 0.180 |
Why?
|
| Cholesterol, LDL | 1 | 2024 | 554 | 0.170 |
Why?
|
| Eye Proteins | 1 | 2021 | 216 | 0.170 |
Why?
|
| Computational Biology | 2 | 2015 | 789 | 0.170 |
Why?
|
| Sodium Compounds | 1 | 2019 | 5 | 0.170 |
Why?
|
| Chemokine CCL20 | 1 | 2019 | 16 | 0.170 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 650 | 0.170 |
Why?
|
| Arsenites | 1 | 2019 | 14 | 0.170 |
Why?
|
| Immunoprecipitation | 3 | 2016 | 197 | 0.170 |
Why?
|
| Pedigree | 2 | 2021 | 1533 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2020 | 174 | 0.170 |
Why?
|
| Caco-2 Cells | 1 | 2019 | 96 | 0.170 |
Why?
|
| Multiprotein Complexes | 3 | 2016 | 207 | 0.170 |
Why?
|
| Exome | 2 | 2014 | 1009 | 0.170 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2022 | 217 | 0.160 |
Why?
|
| Protein Kinase C | 1 | 2019 | 151 | 0.160 |
Why?
|
| Genotype | 2 | 2015 | 2525 | 0.160 |
Why?
|
| Glycogen | 2 | 2015 | 63 | 0.160 |
Why?
|
| Chronic Disease | 1 | 2023 | 1166 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2023 | 1034 | 0.150 |
Why?
|
| Homeodomain Proteins | 1 | 2021 | 541 | 0.150 |
Why?
|
| Child | 6 | 2023 | 24064 | 0.150 |
Why?
|
| Neoplasms, Experimental | 1 | 2019 | 215 | 0.150 |
Why?
|
| Cytokines | 1 | 2024 | 1272 | 0.150 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2019 | 261 | 0.150 |
Why?
|
| Biomarkers, Tumor | 2 | 2015 | 1424 | 0.150 |
Why?
|
| Transfection | 2 | 2017 | 1076 | 0.150 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2016 | 523 | 0.150 |
Why?
|
| Interferon-gamma | 1 | 2020 | 508 | 0.140 |
Why?
|
| RNA, Long Noncoding | 1 | 2020 | 210 | 0.140 |
Why?
|
| Child, Preschool | 5 | 2023 | 13777 | 0.140 |
Why?
|
| Antioxidants | 1 | 2019 | 337 | 0.140 |
Why?
|
| Gluconeogenesis | 1 | 2017 | 107 | 0.140 |
Why?
|
| Heart Function Tests | 1 | 2017 | 57 | 0.140 |
Why?
|
| Databases, Genetic | 2 | 2020 | 463 | 0.140 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2020 | 229 | 0.140 |
Why?
|
| Mutation, Missense | 1 | 2021 | 826 | 0.140 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2017 | 66 | 0.140 |
Why?
|
| Retroviridae | 1 | 2017 | 205 | 0.140 |
Why?
|
| Neurons | 3 | 2011 | 1918 | 0.130 |
Why?
|
| Receptors, CXCR5 | 1 | 2015 | 5 | 0.130 |
Why?
|
| Chemokine CXCL13 | 1 | 2015 | 4 | 0.130 |
Why?
|
| Cytosol | 1 | 2016 | 160 | 0.130 |
Why?
|
| Twist-Related Protein 1 | 1 | 2016 | 36 | 0.130 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2017 | 106 | 0.130 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2016 | 356 | 0.130 |
Why?
|
| Isoleucine-tRNA Ligase | 1 | 2015 | 1 | 0.130 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2017 | 137 | 0.130 |
Why?
|
| Adolescent | 6 | 2023 | 18940 | 0.130 |
Why?
|
| Molecular Structure | 2 | 2013 | 286 | 0.130 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2015 | 75 | 0.130 |
Why?
|
| Leukocyte Common Antigens | 1 | 2015 | 91 | 0.130 |
Why?
|
| Codon, Terminator | 1 | 2015 | 25 | 0.130 |
Why?
|
| Protein Binding | 3 | 2014 | 1732 | 0.130 |
Why?
|
| Glycogenolysis | 1 | 2015 | 9 | 0.120 |
Why?
|
| Serine | 1 | 2016 | 174 | 0.120 |
Why?
|
| Endoderm | 1 | 2015 | 26 | 0.120 |
Why?
|
| Cholestasis | 1 | 2017 | 161 | 0.120 |
Why?
|
| Activins | 1 | 2015 | 78 | 0.120 |
Why?
|
| Rats | 5 | 2014 | 3657 | 0.120 |
Why?
|
| Astragalus Plant | 1 | 2014 | 2 | 0.120 |
Why?
|
| Animals, Genetically Modified | 2 | 2016 | 315 | 0.120 |
Why?
|
| Retrospective Studies | 5 | 2022 | 15853 | 0.120 |
Why?
|
| Follow-Up Studies | 2 | 2022 | 5013 | 0.120 |
Why?
|
| Leber Congenital Amaurosis | 1 | 2014 | 30 | 0.120 |
Why?
|
| Smad8 Protein | 1 | 2014 | 6 | 0.120 |
Why?
|
| Insulin-Like Growth Factor I | 3 | 2012 | 340 | 0.120 |
Why?
|
| Cell Culture Techniques | 1 | 2016 | 288 | 0.120 |
Why?
|
| Quinoxalines | 1 | 2014 | 39 | 0.120 |
Why?
|
| Smad5 Protein | 1 | 2014 | 22 | 0.120 |
Why?
|
| In Vitro Techniques | 1 | 2016 | 968 | 0.120 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2014 | 109 | 0.110 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 712 | 0.110 |
Why?
|
| Plant Exudates | 1 | 2013 | 1 | 0.110 |
Why?
|
| HIV Envelope Protein gp41 | 1 | 2013 | 7 | 0.110 |
Why?
|
| Embryonic Stem Cells | 1 | 2015 | 172 | 0.110 |
Why?
|
| I-kappa B Kinase | 2 | 2016 | 61 | 0.110 |
Why?
|
| Artemisinins | 1 | 2013 | 10 | 0.110 |
Why?
|
| DNA Damage | 2 | 2018 | 516 | 0.110 |
Why?
|
| Pancreatic Neoplasms | 1 | 2020 | 689 | 0.110 |
Why?
|
| Thioredoxins | 1 | 2013 | 23 | 0.110 |
Why?
|
| Amino Acid Motifs | 3 | 2020 | 198 | 0.110 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2013 | 71 | 0.110 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2013 | 89 | 0.110 |
Why?
|
| Zebrafish | 2 | 2016 | 369 | 0.110 |
Why?
|
| Dietary Supplements | 1 | 2017 | 460 | 0.110 |
Why?
|
| Caspase 9 | 1 | 2013 | 75 | 0.110 |
Why?
|
| Lipoproteins, LDL | 1 | 2013 | 114 | 0.110 |
Why?
|
| Genes, Reporter | 2 | 2011 | 384 | 0.110 |
Why?
|
| Stromal Cells | 1 | 2014 | 296 | 0.110 |
Why?
|
| Glucose | 1 | 2017 | 875 | 0.110 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2010 | 546 | 0.110 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2013 | 33 | 0.110 |
Why?
|
| Phylogeny | 1 | 2015 | 681 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 1250 | 0.110 |
Why?
|
| Liver Diseases | 1 | 2017 | 384 | 0.110 |
Why?
|
| Membrane Proteins | 1 | 2020 | 1520 | 0.110 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2016 | 768 | 0.100 |
Why?
|
| RNA | 1 | 2016 | 578 | 0.100 |
Why?
|
| Nickel | 1 | 2012 | 22 | 0.100 |
Why?
|
| Down-Regulation | 4 | 2018 | 702 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2012 | 7 | 0.100 |
Why?
|
| Cell Adhesion Molecules | 1 | 2013 | 223 | 0.100 |
Why?
|
| Copper | 1 | 2012 | 68 | 0.100 |
Why?
|
| Protein Structure, Tertiary | 1 | 2014 | 751 | 0.100 |
Why?
|
| Neoplasm Proteins | 1 | 2016 | 665 | 0.100 |
Why?
|
| Prostate | 1 | 2014 | 422 | 0.100 |
Why?
|
| Caenorhabditis elegans | 1 | 2013 | 220 | 0.100 |
Why?
|
| Cells, Cultured | 5 | 2017 | 3074 | 0.100 |
Why?
|
| Treatment Outcome | 4 | 2022 | 12045 | 0.100 |
Why?
|
| Ion Transport | 1 | 2011 | 49 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2015 | 1296 | 0.100 |
Why?
|
| Smad2 Protein | 1 | 2011 | 49 | 0.100 |
Why?
|
| Female | 14 | 2024 | 64883 | 0.100 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2011 | 239 | 0.090 |
Why?
|
| Sesquiterpenes | 1 | 2011 | 22 | 0.090 |
Why?
|
| Terpenes | 1 | 2011 | 28 | 0.090 |
Why?
|
| Young Adult | 5 | 2016 | 8760 | 0.090 |
Why?
|
| Flow Cytometry | 1 | 2013 | 810 | 0.090 |
Why?
|
| Pyrroles | 1 | 2012 | 177 | 0.090 |
Why?
|
| Phytotherapy | 1 | 2011 | 49 | 0.090 |
Why?
|
| Cholesterol | 1 | 2013 | 521 | 0.090 |
Why?
|
| Rats, Wistar | 1 | 2011 | 356 | 0.090 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2010 | 43 | 0.090 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 303 | 0.090 |
Why?
|
| Ion Channels | 1 | 2011 | 187 | 0.090 |
Why?
|
| Software | 1 | 2015 | 670 | 0.090 |
Why?
|
| Protein Phosphatase 2 | 1 | 2010 | 29 | 0.090 |
Why?
|
| Cytoskeletal Proteins | 1 | 2011 | 268 | 0.090 |
Why?
|
| Myocardial Contraction | 1 | 2011 | 261 | 0.090 |
Why?
|
| Environmental Pollutants | 1 | 2010 | 68 | 0.090 |
Why?
|
| Proteolysis | 2 | 2024 | 170 | 0.090 |
Why?
|
| Alleles | 1 | 2014 | 1579 | 0.090 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2010 | 129 | 0.080 |
Why?
|
| Cytoskeleton | 1 | 2010 | 178 | 0.080 |
Why?
|
| Peptide Fragments | 1 | 2013 | 745 | 0.080 |
Why?
|
| Hydrogen Peroxide | 1 | 2010 | 113 | 0.080 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2014 | 860 | 0.080 |
Why?
|
| Phosphoproteins | 4 | 2013 | 400 | 0.080 |
Why?
|
| Staphylococcus aureus | 1 | 2013 | 457 | 0.080 |
Why?
|
| Cell Nucleus | 1 | 2011 | 678 | 0.080 |
Why?
|
| Binding Sites | 1 | 2011 | 1292 | 0.080 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 3 | 2016 | 163 | 0.080 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2015 | 515 | 0.080 |
Why?
|
| Endothelial Cells | 1 | 2012 | 527 | 0.080 |
Why?
|
| Disease Progression | 1 | 2014 | 1991 | 0.070 |
Why?
|
| Mice, Knockout | 2 | 2016 | 3770 | 0.070 |
Why?
|
| Biomedical Research | 1 | 2013 | 510 | 0.070 |
Why?
|
| Soil | 1 | 2008 | 45 | 0.070 |
Why?
|
| Staphylococcal Infections | 1 | 2013 | 552 | 0.070 |
Why?
|
| Phosphorus | 1 | 2008 | 55 | 0.070 |
Why?
|
| Gene Knockdown Techniques | 3 | 2015 | 351 | 0.070 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2008 | 132 | 0.070 |
Why?
|
| Adult | 6 | 2020 | 28733 | 0.070 |
Why?
|
| Heart | 1 | 2011 | 723 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 2 | 2024 | 979 | 0.070 |
Why?
|
| Mice, Obese | 2 | 2017 | 77 | 0.070 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2020 | 145 | 0.060 |
Why?
|
| Glycogen Synthase Kinases | 2 | 2015 | 6 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2016 | 83 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2018 | 86 | 0.060 |
Why?
|
| Base Sequence | 3 | 2017 | 3109 | 0.060 |
Why?
|
| Up-Regulation | 2 | 2020 | 873 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2020 | 1008 | 0.060 |
Why?
|
| Random Allocation | 2 | 2016 | 417 | 0.060 |
Why?
|
| Recombinant Proteins | 2 | 2020 | 1370 | 0.060 |
Why?
|
| Transcription Factors | 2 | 2011 | 2578 | 0.060 |
Why?
|
| Elastomers | 1 | 2024 | 3 | 0.060 |
Why?
|
| HSP40 Heat-Shock Proteins | 1 | 2024 | 21 | 0.060 |
Why?
|
| Myocardial Infarction | 1 | 2011 | 994 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 3050 | 0.060 |
Why?
|
| Gene Transfer Techniques | 2 | 2017 | 374 | 0.060 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2014 | 132 | 0.050 |
Why?
|
| Temperature | 1 | 2024 | 304 | 0.050 |
Why?
|
| TNF Receptor-Associated Factor 4 | 1 | 2023 | 20 | 0.050 |
Why?
|
| Molecular Chaperones | 1 | 2024 | 169 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 2 | 2015 | 1076 | 0.050 |
Why?
|
| Obesity | 1 | 2013 | 2083 | 0.050 |
Why?
|
| Ubiquitination | 1 | 2023 | 173 | 0.050 |
Why?
|
| Middle Aged | 6 | 2020 | 25640 | 0.050 |
Why?
|
| Pyrazoles | 1 | 2024 | 300 | 0.050 |
Why?
|
| Risk Factors | 4 | 2017 | 9902 | 0.050 |
Why?
|
| Dutasteride | 1 | 2020 | 2 | 0.050 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 2 | 2010 | 20 | 0.050 |
Why?
|
| Chromones | 1 | 2020 | 22 | 0.050 |
Why?
|
| NADP | 1 | 2020 | 48 | 0.050 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2020 | 49 | 0.050 |
Why?
|
| PC12 Cells | 2 | 2010 | 28 | 0.050 |
Why?
|
| Transcription Factor RelA | 1 | 2020 | 53 | 0.040 |
Why?
|
| Morpholines | 1 | 2020 | 55 | 0.040 |
Why?
|
| Receptors, Interleukin-8B | 1 | 2020 | 15 | 0.040 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2020 | 33 | 0.040 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2020 | 102 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2020 | 84 | 0.040 |
Why?
|
| Cervix Uteri | 1 | 2020 | 70 | 0.040 |
Why?
|
| Tumor Escape | 1 | 2020 | 63 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2020 | 233 | 0.040 |
Why?
|
| Oncogenes | 1 | 2020 | 172 | 0.040 |
Why?
|
| Pancreatectomy | 1 | 2020 | 135 | 0.040 |
Why?
|
| HCT116 Cells | 1 | 2019 | 55 | 0.040 |
Why?
|
| Pancreas | 1 | 2020 | 214 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 104 | 0.040 |
Why?
|
| Lung Neoplasms | 2 | 2020 | 1615 | 0.040 |
Why?
|
| Cell Survival | 2 | 2011 | 816 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2018 | 79 | 0.040 |
Why?
|
| Oligoribonucleotides | 1 | 2017 | 9 | 0.040 |
Why?
|
| Phosphoenolpyruvate Carboxykinase (ATP) | 1 | 2017 | 7 | 0.040 |
Why?
|
| Antagomirs | 1 | 2017 | 3 | 0.040 |
Why?
|
| Protein Biosynthesis | 2 | 2012 | 668 | 0.040 |
Why?
|
| Glucose-6-Phosphatase | 1 | 2017 | 19 | 0.040 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2017 | 39 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2020 | 419 | 0.040 |
Why?
|
| HeLa Cells | 2 | 2010 | 808 | 0.040 |
Why?
|
| Cell Cycle Proteins | 2 | 2013 | 657 | 0.040 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2017 | 95 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2020 | 353 | 0.040 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 1 | 2017 | 20 | 0.040 |
Why?
|
| Drugs, Chinese Herbal | 1 | 2017 | 18 | 0.040 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2017 | 58 | 0.040 |
Why?
|
| Prognosis | 2 | 2017 | 4488 | 0.030 |
Why?
|
| Sendai virus | 1 | 2016 | 4 | 0.030 |
Why?
|
| Vesiculovirus | 1 | 2016 | 12 | 0.030 |
Why?
|
| Interferon Regulatory Factor-3 | 1 | 2016 | 17 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 6291 | 0.030 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2016 | 51 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2020 | 1468 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 548 | 0.030 |
Why?
|
| Embryo, Nonmammalian | 1 | 2016 | 141 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2017 | 194 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2015 | 92 | 0.030 |
Why?
|
| Plant Extracts | 1 | 2017 | 117 | 0.030 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2015 | 78 | 0.030 |
Why?
|
| Diet, High-Fat | 1 | 2017 | 206 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2016 | 231 | 0.030 |
Why?
|
| Fetal Proteins | 1 | 2015 | 13 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2015 | 230 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2015 | 108 | 0.030 |
Why?
|
| SOXF Transcription Factors | 1 | 2015 | 16 | 0.030 |
Why?
|
| Pteridines | 1 | 2014 | 8 | 0.030 |
Why?
|
| Bone Morphogenetic Protein 6 | 1 | 2014 | 10 | 0.030 |
Why?
|
| Phenylthiohydantoin | 1 | 2014 | 12 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2015 | 333 | 0.030 |
Why?
|
| Hepatectomy | 1 | 2015 | 122 | 0.030 |
Why?
|
| Protein Domains | 1 | 2016 | 228 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 2017 | 523 | 0.030 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2015 | 38 | 0.030 |
Why?
|
| Receptors, CXCR4 | 1 | 2015 | 58 | 0.030 |
Why?
|
| Inhibitor of Differentiation Protein 1 | 1 | 2014 | 5 | 0.030 |
Why?
|
| Imines | 1 | 2014 | 9 | 0.030 |
Why?
|
| Cyclization | 1 | 2014 | 15 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2018 | 1354 | 0.030 |
Why?
|
| Quantum Theory | 1 | 2014 | 15 | 0.030 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2015 | 74 | 0.030 |
Why?
|
| Oxides | 1 | 2014 | 15 | 0.030 |
Why?
|
| Hydrogen | 1 | 2014 | 38 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 268 | 0.030 |
Why?
|
| Aged | 3 | 2020 | 18785 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2015 | 388 | 0.030 |
Why?
|
| Models, Animal | 1 | 2016 | 465 | 0.030 |
Why?
|
| Benzamides | 1 | 2014 | 107 | 0.030 |
Why?
|
| Anti-Infective Agents | 1 | 2017 | 266 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2015 | 461 | 0.030 |
Why?
|
| RNA Polymerase II | 1 | 2014 | 100 | 0.030 |
Why?
|
| Mesoderm | 1 | 2014 | 116 | 0.030 |
Why?
|
| Carbon | 1 | 2014 | 90 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 267 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2014 | 230 | 0.030 |
Why?
|
| Nitriles | 1 | 2014 | 145 | 0.030 |
Why?
|
| Serine Endopeptidases | 1 | 2014 | 175 | 0.030 |
Why?
|
| Catalytic Domain | 1 | 2014 | 154 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2015 | 398 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2016 | 249 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 872 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 2015 | 613 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2013 | 54 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2013 | 96 | 0.030 |
Why?
|
| Osteoblasts | 1 | 2014 | 151 | 0.030 |
Why?
|
| Cathelicidins | 1 | 2013 | 11 | 0.030 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2013 | 86 | 0.030 |
Why?
|
| Teichoic Acids | 1 | 2013 | 13 | 0.030 |
Why?
|
| Animals, Newborn | 1 | 2017 | 1007 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2013 | 312 | 0.030 |
Why?
|
| Macrophage Activation | 1 | 2013 | 62 | 0.030 |
Why?
|
| Genes, p53 | 1 | 2013 | 215 | 0.030 |
Why?
|
| Stereoisomerism | 1 | 2012 | 104 | 0.030 |
Why?
|
| Catalysis | 1 | 2012 | 124 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 1298 | 0.030 |
Why?
|
| Time Factors | 2 | 2015 | 6182 | 0.020 |
Why?
|
| Antifungal Agents | 1 | 2014 | 292 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 1000 | 0.020 |
Why?
|
| Insulin | 1 | 2017 | 1191 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 717 | 0.020 |
Why?
|
| Protein Stability | 1 | 2012 | 166 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2011 | 112 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2014 | 1213 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 1871 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2013 | 1004 | 0.020 |
Why?
|
| Visual Acuity | 1 | 2016 | 803 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2011 | 111 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2013 | 290 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2011 | 284 | 0.020 |
Why?
|
| Receptors, Somatomedin | 1 | 2010 | 25 | 0.020 |
Why?
|
| Caspase 7 | 1 | 2010 | 6 | 0.020 |
Why?
|
| Family | 1 | 2014 | 565 | 0.020 |
Why?
|
| bcl-X Protein | 1 | 2010 | 32 | 0.020 |
Why?
|
| Caspase Inhibitors | 1 | 2010 | 29 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2010 | 63 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2010 | 43 | 0.020 |
Why?
|
| cdc42 GTP-Binding Protein | 1 | 2010 | 31 | 0.020 |
Why?
|
| Androstadienes | 1 | 2010 | 49 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2010 | 54 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2010 | 51 | 0.020 |
Why?
|
| Retinoblastoma Protein | 1 | 2010 | 76 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2010 | 56 | 0.020 |
Why?
|
| Okadaic Acid | 1 | 2010 | 14 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2013 | 637 | 0.020 |
Why?
|
| Cyclins | 1 | 2010 | 104 | 0.020 |
Why?
|
| Acetylcysteine | 1 | 2010 | 74 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2011 | 387 | 0.020 |
Why?
|
| NADPH Oxidases | 1 | 2010 | 115 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 2080 | 0.020 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2010 | 39 | 0.020 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2010 | 51 | 0.020 |
Why?
|
| Oxidants | 1 | 2010 | 25 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2013 | 969 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2015 | 1118 | 0.020 |
Why?
|
| Genes, Dominant | 1 | 2010 | 244 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 1679 | 0.020 |
Why?
|
| Incidence | 1 | 2017 | 3018 | 0.020 |
Why?
|
| Calcium Signaling | 1 | 2011 | 241 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2010 | 241 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 2817 | 0.020 |
Why?
|
| Luminescent Measurements | 1 | 2008 | 57 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2011 | 352 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 1674 | 0.020 |
Why?
|
| Diffusion | 1 | 2008 | 58 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2008 | 316 | 0.020 |
Why?
|
| Calibration | 1 | 2008 | 83 | 0.020 |
Why?
|
| Neurodegenerative Diseases | 1 | 2010 | 251 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2014 | 3229 | 0.020 |
Why?
|
| Models, Biological | 1 | 2011 | 1438 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 4282 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2012 | 2441 | 0.020 |
Why?
|
| Biomarkers | 1 | 2015 | 2933 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2010 | 1015 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 2385 | 0.020 |
Why?
|
| Proteins | 1 | 2010 | 1043 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2016 | 2997 | 0.010 |
Why?
|
| Infant | 1 | 2016 | 12302 | 0.010 |
Why?
|